Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Thoracic 1NET 1

Conditions

Carcinoma, Neuroendocrine 5Neoplasms 3Vipoma 2Somatostatinoma 2Neuroendocrine Tumors 2Insulinoma 2Glucagonoma 2Gastrinoma 2Carcinoma, Islet Cell 2Adenoma, Islet Cell 2Thyroid Carcinoma, Anaplastic 1Lung Neoplasms 1Head and Neck Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Octreotide 3Leucovorin 3Trastuzumab 2Temozolomide 2Oxaliplatin 2Fluorouracil 2Capecitabine 2veliparib 1vatalanib 1tipifarnib 1pentetreotide 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Melphalan 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1Gefitinib 1Floxuridine 1Fentanyl 1Biological Therapy 1Bevacizumab 190Y-octreotide, DOTA-Tyr(3)- 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Vipoma × Fluorouracil × Endocrine × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT00416767 2016-05-30

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Federation Francophone de Cancerologie Digestive

Phase 2 Completed
20 enrolled
Endocrine

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡